MARKET

BLRX

BLRX

BioLine RX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.330
+0.020
+0.87%
Opening 15:07 12/04 EST
OPEN
2.280
PREV CLOSE
2.310
HIGH
2.370
LOW
2.280
VOLUME
546.97K
TURNOVER
--
52 WEEK HIGH
3.300
52 WEEK LOW
1.061
MARKET CAP
49.87M
P/E (TTM)
-1.0610
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Here is What Hedge Funds Think About Bioline RX Ltd (BLRX)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
Insider Monkey · 2d ago
Fusion Pharmaceuticals (FUSN) Jumps: Stock Rises 9%
Fusion Pharmaceuticals (FUSN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Zacks · 3d ago
AHT, FCEL, AIM and MARA among midday movers
Gainers: DPW Holdings (DPW) +179%.Ideanomics (IDEX) +65%.Fuel Tech (FTEK) +61%.Greenland Technologies (GTEC) +52%.Kaixin Auto (KXIN) +52%.FuelCell Energy (FCEL) +45%.CIIG Merger (CIIC) +37%.Graybug Vision (GRAY) +36%.Beam Global (BEEM) +35%.Marathon Patent (MARA) +33%.Losers: Bellerophon Therapeutics
Seekingalpha · 11/23 17:42
Medigus, 180 Life Sciences leads healthcare gainers; Bellerophon Therapeutics, BioLineRx among major losers
Gainers: Medigus (MDGS) +36%, 180 Life Sciences (ATNF) +35%, Graybug Vision (GRAY) +23%, Trinity Biotech (TRIB) +18%, Accuray (ARAY) +14%.Losers: Bellerophon Therapeutics (BLPH) -18%, BioLineRx (BLRX) -13%, AIM ImmunoTech (AIM) -11%, iBio (IBIO) -10%, OptiNose (OPTN) -10%.
Seekingalpha · 11/23 16:25
BioLineRx down 12% despite Q3 earnings beat
BioLineRx (BLRX) Q3 results:Revenues: $0; R&D Expense: $3.5M (-37.5%); Net loss: ($4.6M) (-17.9%); loss/share: ($0.02) (+33.3%); Quick Assets: $20.8M ; CF Ops: ($17.8M) (+3.5%).During the quarter, the company reported interim
Seekingalpha · 11/23 14:06
Root, Niu Technologies leads the premarket losers pack
Ashford Hospitality Trust (AHT) -21% on update of exchange offers for all outstanding series of preferred stock.BioLineRx (BLRX) -13% on Q3 earnings release.AIM ImmunoTech (AIM) -8% after AIM and Shionogi terminated their material transfer agreement.Niu
Seekingalpha · 11/23 13:37
BioLineRx Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 23, 2020 / BioLineRx Ltd. (NASDAQ:BLRX) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 23, 2020 at 10:00 AM Eastern Time.
ACCESSWIRE · 11/23 13:16
BioLineRx Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 23, 2020 / BioLineRx Ltd.
ACCESSWIRE · 11/23 13:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLRX. Analyze the recent business situations of BioLine RX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLRX stock price target is 11.33 with a high estimate of 18.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 4.33M
% Owned: 20.23%
Shares Outstanding: 21.41M
TypeInstitutionsShares
Increased
4
326.35K
New
6
696.49K
Decreased
3
136.96K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.68%
Pharmaceuticals & Medical Research
+1.47%
Key Executives
Chairman/Director
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Chief Scientific Officer
Merril Gersten
Vice President
Ella Sorani
Vice President
Moshe Phillip
Vice President
Abi Vainstein-Haras
Vice President - Business Development
David Malek
Vice President - Business Development
Hillit Mannor Shachar
Director
Michael Anghel
Director
Barbara-Jean Bormann
Director
Raphael Hofstein
General Manager
Leah Klapper
Director
Sandra Panem
Non-Executive Director
Nurit Benjamini
Director
Jacob Friedman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of BioLine RX Ltd stock information, including NASDAQ:BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.